Jounce Therapeutics Inc

-0.03 (-0.64%)
Earnings Announcements

Jounce Therapeutics Reports Q2 2022 Financial Results

Published: 08/04/2022 11:55 GMT
Jounce Therapeutics Inc (JNCE) - Jounce Therapeutics Reports Second Quarter 2022 Financial Results.
Ended Quarter With $162.3 Million in Cash, Cash Equivalents and Investments.
Qtrly Net Loss Was $33.5 Million for Q2 of 2022, Resulting in Basic and Diluted Net Loss per Share of $0.65.
Q2 Earnings per Share View $-0.68 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $2.5 Million
Adjusted EPS is expected to be -$0.62

Next Quarter Revenue Guidance is expected to be $15.63 Million
Next Quarter EPS Guidance is expected to be -$0.46

More details on our Analysts Page.